Regulatory press releases

Kommuniké från extra bolagsstämma i Nanologica AB (publ)

7 February, 2022

Nanologica AB (publ) (”Bolaget”) höll idag den 7 februari 2022 extra bolagsstämma, varvid beslutet nedan fattades. För mer detaljerad information om innehållet i beslutet hänvisas till den fullständiga kallelsen till den extra bolagsstämman. Kallelse till extra bolagsstämma samt fullständiga förslag finns tillgängliga på Bolagets webbplats, www.nanologica.com. Protokoll från den extra bolagsstämman kommer att tillhandahållas på nämnda webbplats inom två veckor från dagen för stämman. Beslut om godkännande av låneavtal med Flerie Invest AB I enlighet

Kallelse till extra bolagsstämma i Nanologica AB (publ)

19 January, 2022

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023, (”Bolaget”) kallas härmed till extra bolagsstämma måndagen den 7 februari 2022 kl. 10.00. Stämman hålls i Redeyes lokaler på Mäster Samuelsgatan 42 i Stockholm. I syfte att minska risken för spridning av covid-19 (coronaviruset) kommer antalet närvarande deltagare som inte är aktieägare att begränsas, ingen mat eller dryck kommer att serveras och planerade anföranden kommer att begränsas i tid. Aktieägare med förkylnings- eller influensaliknande symptom, även milda sådana,

Nanologica Changes Dates for Financial Reports

19 January, 2022

Nanologica’s Year-end report for 2021 will be published on Tuesday February 8, instead of January 31 as previously announced, and the company’s Annual Report for 2021 will be published on Wednesday March 9, instead of April 8 as previously announced. Dates for upcoming financial reports: Year-end report 2021 8 February, 2022 Annual Report 2021 9 March,

Nanologica Signs Credit Line with Main Owner

19 January, 2022

Nanologica AB has signed a credit line of up to MSEK 50 with the company’s main owner Flerie Invest AB. The aim is to cover the company’s temporary financial needs pending expected cash flows from the preparative chromatography business, to meet the requirement of going concern for the next twelve months. This loan financing is a flexible way to meet the company’s short-term capital needs pending expected cash flows from the preparative chromatography business. The

Stock option program in Nanologica ab fully subscribed

20 December, 2021

The option program 2021/24 for Nanologica AB resolved by the Annual General Meeting 2021 has now been implemented. The program was subscribed at 100 percent by both the management team, including the CEO, and employees. At the Annual General Meeting on May 27, 2021, a new stock option program was resolved, which has now been implemented. In option program 2021/24 for Nanologica’s management and employees, 800,000 of the total 800,000 options have been subscribed for.

Nanologica Recruits VP Chromatography

6 December, 2021

Nanologica has recruited Katarina Alenäs as VP Chromatography to lead Nanologica’s sales organization within Chromatography globally. As sales start for preparative chromatography approaches, Nanologica’s sales organization is now strengthened with Katarina Alenäs as VP Chromatography. The assignment includes leading the sales organization and driving the work globally. Nanologica thus has its own sales organization covering all major markets – India, China, US and Europe. ” With solid experience from the biotechnology industry in general and

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.